Journal article
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
Cancer, Vol.123(1), pp.90-97
01/01/2017
DOI: 10.1002/cncr.30379
PMID: 27696380
Abstract
Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that are relatively resistant to chemotherapy and for which more effective drug therapy is needed.
The 5 listed subtypes were enrolled into a single indolent sarcoma cohort in a phase 2 study of dasatinib using a Bayesian continuous monitoring rule for enrollment. The primary objective was to estimate the 6-month progression-free survival (PFS) rate according to the Choi criteria with a target of ≥50%. Cross-sectional imaging was performed before the start of treatment, every 2 months for 6 months, and then every 3 months during treatment. The 2- and 5-year survival rates were determined.
One hundred sixteen patients were enrolled within 45 months, and 109 began treatment with dasatinib. The 6-month PFS rate and the median PFS were 48% and 5.8 months, respectively. The PFS rate at 6 months was highest with ASPS (62%) and lowest with SFT (30%). More than 10% of the patients with ASPS, CS, or chordoma had stable disease for more than 1 year. Collectively, for all 5 subtypes, the 2- and 5-year overall survival rates were 44% and 13%, respectively. An objective response was observed in 18% of the patients with CS or chordoma.
Dasatinib failed to achieve control of sarcoma growth for at least 6 months in more than 50% of the patients in this trial according to the Choi tumor response criteria. An objective tumor response and prolonged stable disease was observed in >10% of patients with CS or chordoma. Cancer 2017;90-97. © 2016 American Cancer Society.
Details
- Title: Subtitle
- Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
- Creators
- Scott M Schuetze - University of Michigan–Ann ArborVanessa Bolejack - Cancer Research And BiostatisticsEdwin Choy - Harvard UniversityKristen N Ganjoo - Stanford UniversityArthur P Staddon - University of PennsylvaniaWarren A Chow - City Of Hope National Medical CenterHussein A Tawbi - The University of Texas MD Anderson Cancer CenterBrian L Samuels - Northwest OncologyShreyaskumar R Patel - The University of Texas MD Anderson Cancer CenterMargaret von Mehren - Fox Chase Cancer CenterGina D'Amato - Georgia Cancer SpecialistsKirsten M Leu - Nebraska Cancer SpecialistsDavid M Loeb - Johns Hopkins UniversityCharles A Forscher - Cedars-Sinai Medical CenterMohammed M Milhem - University of IowaDaniel A Rushing - University of IndianapolisDavid R Lucas - University of Michigan–Ann ArborRashmi Chugh - University of Michigan–Ann ArborDenise K Reinke - Sarcoma Alliance for Research through CollaborationLaurence H Baker - University of Michigan–Ann Arbor
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.123(1), pp.90-97
- DOI
- 10.1002/cncr.30379
- PMID
- 27696380
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Grant note
- P30 CA006927 / NCI NIH HHS
- Language
- English
- Date published
- 01/01/2017
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359780902771
Metrics
8 Record Views